drugset / Trial / NCT02257021

Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers

NCT02257021

Phase 1 Completed 34 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine the effect of BILR 355/r on tipranavir/r pharmacokinetics and the effect of tipranavir/r on BILR 355 BS pharmacokinetics

Timeline

Start
2005-02
Primary completion
2005-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BILR 355 BS Unknown
Subject Ritonavir Other / unclassified
Subject Tipranavir Small molecule

Indications

No indication recorded.